A record-linkage study of the development of hepatocellular carcinoma in persons with hepatitis C infection in Scotland by McDonald, S A et al.
A record-linkage study of the development of hepatocellular
carcinoma in persons with hepatitis C infection in Scotland
SA McDonald*,1, SJ Hutchinson
1,2, SM Bird
3, C Robertson
1,2, PR Mills
4, JF Dillon
5 and DJ Goldberg
1
1Health Protection Scotland, Clifton House, Clifton Place, Glasgow G3 7LN, UK;
2Department of Statistics and Modelling Science, University of
Strathclyde, Richmond Street, Glasgow G1 1XH, UK;
3MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Robinson Way, Cambridge
CB2 2SR, UK;
4Gartnavel General Hospital, 1053 Great Western Road, Glasgow G12 0YN, UK;
5Ninewells Hospital and Medical School, Dundee DD1
9SY, UK
We investigated trends in first-time hospital admissions and deaths attributable to hepatocellular carcinoma (HCC) in a large
population-based cohort of 22073 individuals diagnosed with hepatitis C viral (HCV) infection through laboratory testing in Scotland
in 1991–2006. We identified new cases of HCC through record-linkage to the national inpatient hospital discharge database and
deaths registry. A total of 172 persons diagnosed with HCV were admitted to hospital or died with first-time mention of HCC.
Hepatocellular carcinoma incidence increased between 1996 and 2006 (average annual change of 6.1, 95% confidence interval (CI):
0.9–11.6%, P¼0.021). The adjusted relative risk of HCC was greater for males (hazard ratio¼2.7, 95% CI: 1.7–4.2), for those aged
60 years or older (hazard ratio¼2.7, 95% CI: 1.9–4.1) compared with 50–59 years, and for those with a previous alcohol-related
hospital admission (hazard ratio¼2.5, 95% CI: 1.7–3.7). The risk of individuals diagnosed with HCV developing HCC was greatly
increased compared with the general Scottish population (standardised incidence ratio¼127, 95% CI: 102–156). Owing to the
advancing age of the Scottish HCV-diagnosed population, the annual number of HCC cases is projected to increase, with a
consequent increasing burden on the public healthcare system.
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The aetiology of hepatocellular carcinoma (HCC) includes
excessive alcohol consumption and chronic infection with the
hepatitis B or C virus. The incidence of HCC has increased in
developed countries worldwide (Deuffic et al, 1999; El-Serag and
Mason, 1999; Law et al, 2000), but data are limited on its cause.
However, modelling initiatives have projected increasing numbers
of HCC deaths attributable to hepatitis B and/or hepatitis C virus
(HCV) infection (Deuffic-Burban et al, 2004, 2007; Sweeting et al,
2007).
In Scotland, HCV is responsible for a significant burden on
healthcare (Hutchinson et al, 2006). Meeting the public health
challenge of providing sufficient resources for treatment and care
of patients with HCV requires up-to-date data on morbidity and
mortality. However, national surveillance systems for detecting
advanced HCV-related liver disease are currently lacking in the United
Kingdom and elsewhere. The existence of high-quality national HCV
diagnosis and hospital discharge databases provided the opportunity to
use record-linkage techniques to investigate the annual number of new
diagnoses of, and deaths from, HCV-related HCC.
Our principal goal was to investigate trends in the annual
incidence of HCC in the entire HCV-diagnosed population in
Scotland through record linkage to hospital admission and deaths
records. We also aimed to confirm previously reported associa-
tions between risk factors and progression to HCC. Up-to-date
information regarding factors affecting the rate of development of
HCC in individuals diagnosed with HCV is needed for informing
clinical management and care, and for refining guidelines for early
detection.
MATERIALS AND METHODS
The design was an observational record-linkage study involving
national HCV diagnosis and hospital discharge databases and the
national deaths and cancer registries, and subsequent analyses of
the incidence of HCC among a retrospective cohort of all persons
diagnosed with HCV infection. HCV-related HCC incidence was
calculated using hospital discharge data, as this was available until
2006, and validated against cancer registrations (available until
2004).
Health Protection Scotland (HPS) maintains a database of all
persons who have been diagnosed as HCV positive in Scotland
since testing commenced in 1991 (Shaw et al, 2003); laboratory
detection of hepatitis C antibody is a requirement for inclusion.
This database contains the following non-named information:
surname soundex code, forename initial, date of birth, sex, and the
first part of the postcode of residence, as well as data concerning
risk activities. As of 31 December 2006, the database contained
records for 22073 persons diagnosed as HCV positive (HPS, 2007),
who comprise the study population. Received 2 May 2008; revised 2 July 2008; accepted 21 July 2008
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patient record held by Information Services Division (ISD) of all
general acute inpatient and day case hospital discharges. Discharge
diagnoses use International Classification of Diseases (ICD) Ninth
Revision for discharges from 1989 to 1995, and Tenth Revision for
discharges from 1996 to 2006. The Scottish Morbidity Cancer
Records (SMR06) is a national database containing all cancer
notifications in Scotland; data include date of registration and
cancer site (but not aetiology) and were available up to the end of
2004. ISD routinely combines the SMR01 and SMR06 data with
death registrations held by the General Register Office for Scotland
to form a linked data set.
Linkage of records between the HCV diagnosis database and the
previously linked SMR01/SMR06/deaths registry was carried out
by ISD using probabilistic record-linkage techniques (Kendrick
and Clarke, 1993). ISD had previously estimated the error rate
(either false positives or false negatives) of their procedure to be
less than 5% (Kendrick and Clarke, 1993). The resulting linked
data set was anonymised before transfer to HPS for analysis.
Linkages were approved by the Privacy Advisory Committee,
which advises on confidentiality issues involving data held on NHS
Scotland patients.
The main outcome of interest was the annual numbers of first
hospital admissions (or death, if no previous admission) with
mention of HCC. Combining admission and death information to
estimate the annual incidence of HCC is justified because of the
relatively short lag (see Results) between first HCC admission and
death. Diagnosis/cause-of-death codes indicated the development
of HCC; specifically, ICD-10 C22.0 or ICD-9 155.0 mentioned as
either a primary or secondary discharge diagnosis in a linked
SMR01 hospitalisation record, or as either the underlying or a
contributing cause of death in a linked death record. The terms
admission and discharge are used interchangeably; it is assumed
that discharge diagnosis codes encode the reason(s) for admission.
Data analysis
No probabilistic linkages to the linked SMR01/06/death records
were achieved if the HCV record lacked date of birth and two or
more other identifiers. By these criteria, records for 1324 out of
22073 persons had insufficient identifiers and thus were excluded
from further analyses.
We carried out two types of analyses. First, annual trends in the
numbers of persons diagnosed with HCV developing HCC were
estimated using Poisson regression. We analysed annual trends in
counts rather than rates because the expansion of the HCV
diagnosis database since its inception – with increasing propor-
tions of persons at earlier stages of disease progression being
identified and added – means that rates calculated for recent years
would reflect more outcome-free person-years of follow-up than
rates for earlier years. The eligible population was restricted to
those with an HCV diagnosis date before or within 1 year after
their first hospital admission for HCC. Data for individuals for
whom first mention of HCC occurred more than 1 year before their
HCV diagnosis date were excluded (n¼6), as were individuals
who died from any cause more than 1 year before HCV diagnosis
(n¼23). Of the 20749 persons diagnosed with HCV with sufficient
identifiers for record linkage, 20720 met this 1-year constraint.
Analysis of annual counts was restricted to the period 1996–2006,
owing to limited HCV antibody testing before 1996. We
additionally compared the annual incidence of diagnosed HCV-
related HCC derived from the hospital discharge/death records
linkage with the corresponding annual numbers of linked SMR06
cancer registrations over the period 1996–2004.
Second, an analysis of time from HCV diagnosis to first
admission/death with mention of HCC was undertaken. The
observation period was defined to start 14 days after HCV
diagnosis; thus records for persons diagnosed within the 14-day
period before 31 December 2006 (n¼44) and persons first
hospitalised for HCC or who died of any cause before HCV
diagnosis (n¼328), or within 14 days following this date (n¼154),
were excluded. Of the excluded records, 28 were first diagnosed as
HCV positive subsequent to their first hospital admission for HCC
and 300 were first diagnosed after death. Nine individuals were
first hospitalised with HCC, 3 died with mention of HCC, and 142
died of other causes within 14 days of HCV diagnosis. Confining
analysis to persons who are outcome free at the start of follow-up
reduces bias due to an increased risk of hospitalisation at the time
of diagnosis for patients presenting with established disease. Time
at risk (in person-years) was then calculated from the start of the
observation period to the earliest of first hospital admission for
HCC, date of death or the end of the observation period (31
December 2006). Records for 20223 individuals diagnosed with
HCV were eligible for this analysis.
We used Cox proportional hazards regression analysis to assess
the strength of association between risk factors (given below) and
the time to first hospital admission/death with mention of HCC.
Age and whether the person had a previous admission for an
alcohol-related condition were treated as time-dependent covari-
ates; sex was included as a time-independent covariate. Previous
admission with mention of hepatitis B virus (HBV) infection was
not included in the multifactorial analysis, as it was unassociated
with the risk of developing HCC. Human immunodeficiency virus
(HIV)-co-infected status was also considered as a covariate, but
record linkage to a national HIV diagnosis database indicated no
HCC cases to be HIV-co-infected (McDonald et al, in press).
Kaplan–Meier methods were used to estimate the age-dependent
probability of developing HCC, according to sex, risk activity
leading to infection, and whether or not the person had a previous
admission with mention of cirrhosis or an alcohol-related
condition.
We computed standardised incidence ratios (SIRs) for HCC in
the HCV-diagnosed population by age, sex, and calendar-year
standardising to expected incidence rates derived from all HCC
registrations in Scotland during 1996–2004 and the national mid-
year population estimates for the same period (ISD, 2008). All data
analyses were carried out using R version 2.4.0 (R Foundation for
Statistical Computing, 2006).
For each person diagnosed with HCV, the occurrence of at least
one alcohol-related hospital episode was coded as a time-
dependent variable. This involved searching the linked hospital
records for alcohol-related discharges occurring before the date of
first mention of HCC, or, for those with no HCC admission/death,
at any time before 31 December 2006. The set of alcohol-related
diagnosis codes comprised alcohol use (ICD-10 Z72.1), mental and
behavioural disorders due to use of alcohol (ICD-10 F10; ICD-9:
291, 303, 305), degeneration of nervous system due to alcohol
(ICD-10 G31.2, G62.1, G72.1, I42.6, K29.2; ICD-9 357.5, 425.5,
535.3), toxic effects of alcohol (ICD-10 T51.0, T51.9; ICD-9 980.0),
alcoholic liver disease (ICD-10 K70.1-3; ICD-9 571.0–571.2),
alcohol-induced chronic pancreatitis (ICD-10 K86.0), evidence of
alcohol involvement (ICD-10 Y90-1), finding of alcohol in blood
(ICD-10 R78.0; ICD-9 790.3), alcohol rehabilitation (ICD-10 Z50.2),
personal history of psychoactive substance abuse (ICD-10 Z86.4;
captures non-current mental/behavioural disorders due to use of
alcohol), and accidental or intentional self-poisoning by and
exposure to alcohol (ICD-10 X45, X65; ICD-9 E860.0, E860.9).
Additional risk factors identified by previous research as
predictors of the development of HCC were coded for each
person. These included age (time-dependent: o50, 50–59 and
60þ years) and reported risk activity leading to infection
(injecting drug use (IDU), non-IDU, not known). The non-IDU
group included persons who had reported potential acquisition of
HCV infection through receipt of blood or blood products, tattoo/
body piercing, needlestick injury, sexual contact, or perinatal
transmission. Previous hospitalisation for cirrhosis was also
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biliary cirrhosis among the discharges occurring before first
mention of HCC, or at any time before 31 December 2006 for those
with no admission/death for HCC. Cirrhosis codes comprised
alcoholic cirrhosis of liver (ICD-10 K70.3; ICD-9 571.2), cirrhosis
of liver without mention of alcohol (ICD-9 571.5), and other and
unspecified cirrhosis of liver (ICD-10 K74.6). The occurrence of a
previous hospital discharge with mention of HBV (ICD-10 B16,
B18.0, B18.1; ICD-9 070.2, 070.3) was similarly noted.
RESULTS
The majority (68%) of the study population were male (Table 1); at
the time of HCV diagnosis, 42% were under the age of 30 years and
13% were 45 years or older (median¼32 years). A total of 31% had
a previous hospital discharge related to alcohol, 3.5% for cirrhosis,
and 5.6% with mention of hepatitis B.
Over a median follow-up of 5.6 years (range¼0–22.0) for all
20720 persons diagnosed with HCV, 172 were either admitted with
first-time mention of HCC (n¼145) or died without being
previously hospitalised with HCC (n¼27); that is, their first and
only indication of HCC was recorded on the death record. The
median time from HCV diagnosis date to first-time mention of
HCC was 2.3 years (0.2, 1.7, and 3.5 years, for HCC calendar
periods o1996, 1996–2000, and 42000, respectively). Of the 145
individuals first hospitalised with HCC, 115 subsequently died, of
whom 95 had their underlying or a contributing cause of death
recorded as HCC; 55% (11 out of 20) of the other deaths specified a
liver-related underlying cause. Twenty-two out of 172 individuals
were diagnosed with HCV following their first HCC admission/
death; the majority of these diagnoses were made within 2 weeks
(n¼19) of first HCC admission/death.
For those individuals who died with an underlying cause of HCC
(tumour) subsequent to their first hospitalisation for HCC
(n¼83), the median lag between first-time admission and death
was 81 days. Forty-four per cent (76 out of 172) of HCC cases had a
previous admission for cirrhosis, and 31% (53 out of 172) had a
previous alcohol-related hospitalisation. The median lag between
first admission for cirrhosis and first-time mention of HCC was 2.3
years. Among only those persons hospitalised for cirrhosis, the
one- and two-year cumulative risks of developing HCC following
first admission for cirrhosis were 3.5 and 6%, respectively.
Hepatitis C virus was listed as a discharge diagnosis in 39% (56
out of 145) of HCC admissions, and as the underlying or a
contributing cause in 41% (11 out of 27) of deaths with first-time
mention of HCC.
Table 2 shows the number of first-time hospital admissions/
deaths per year over the period 1996–2006, stratified by age group
at admission/death. There was a significant increasing trend in the
overall number of first-time admissions/deaths (average annual
change¼6.1%, 95% CI: 0.9–11.6%, P¼0.021). Incorporation of a
year by age-group interaction term indicated a significantly greater
mean annual change in the 50–59 years age group (16.3%, 95%
CI: 6.1–27.5%, P¼0.028) compared with the o50 years age group.
The incidence of HCC in the HCV-diagnosed population as
determined from hospital discharge/death records was compared
with the linked (HCV-related) SMR06 cancer registrations over the
period 1996–2004. There was good agreement between the annual
numbers of first-time HCC admissions/deaths and the SMR06
data. In the study period, there were 108 new entries for HCC in
the cancer registry (12, 16, 4, 11, 6, 13, 15, 14, and 17 registrations
for the years 1996 through 2004, respectively), 7 fewer than the 115
new cases of HCC determined from the hospital admission/death
record linkage in the same period. Three of the cases absent from
the linked cancer registrations were deaths without previous
admission for HCC. Five of the 108 cancer registrations were not
found in the hospital admission/death record linkage.
Figure 1 shows the age-dependent proportion of persons with a
first-time hospitalisation/death with mention of HCC as a function
of sex and whether or not the person had a previous alcohol- or
cirrhosis-related admission. There was no difference in the
unadjusted cumulative probability of developing HCC according
to previous alcohol-related admission status (log-rank test,
P¼0.41). In contrast, a previous admission for cirrhosis was
associated with a much greater proportion of persons developing
HCC (Po0.001).
Table 3 shows adjusted hazard ratios derived from multifactorial
Cox proportional hazards regression analysis, with sex, current age
(o50, 50–50, and 60þ years), and previous alcohol-related
admission as covariates. Violation of the proportional hazards
assumption was assessed graphically and tested using Schoenfield
residuals (global P¼0.63). Males were more likely than females to
develop HCC (hazard ratio¼2.7, 95% CI: 1.7–4.2). Compared with
the reference age group (50–59 years), older age (60þ years) was
associated with an increased risk of first-time admission/death
(HR¼2.7, 1.9–4.1) and younger age (o50 years) with a decreased
risk (HR¼0.03, 95% CI: 0.02–0.05); there was a 2.5-fold increased
risk associated with a previous alcohol-related admission
(HR¼2.5, 95% CI: 1.7–3.7).
Over the period 1996–2004, a total of 1304 HCC cases were
registered in Scotland (ISD, 2008). The estimated prevalence of
diagnosed HCV infection among all HCC cases was therefore 8.8%
(115 out of 1304; 1996–1999 only: 8.4% (45 out of 535);
2000–2004: 9.1% (70 out of 769)). The SIR for HCC was 127
(95% CI: 102–156). We also calculated separate SIRs for males and
females: 118 (95% CI: 93–149) and 179 (95% CI: 106–283),
respectively.
Over the entire observation period (1991–2006), 108 HCV-
diagnosed persons died with an underlying cause of death recorded
as HCC, representing 4% of all deaths (n¼2622) that occurred during
this period. One- and two-year probabilities of death with mention of
HCC subsequent to first-time hospitalisation for HCC were 53 and
Table 1 Characteristics of persons in the national HCV diagnosis
database whose records contained sufficient identifiers for record-linkage,
and the HCV diagnosis date was no more than 1 year following the first
mention of HCC, if any (data up to 31 December 2006; N¼20720)
Variable Group N (%)
Sex Male 14082 (68.0)
Female 6597 (31.8)
Not known 41 (0.2)
Age at HCV diagnosis (years) o30 8673 (41.8)
30–44 9320 (45.0)
45+ 4726 (13.2)
Period of HCV diagnosis Pre-1996 3336 (16.1)
1996–2000 7939 (38.5)
2001–2006 9445 (45.6)
Risk group IDU 12560 (60.6)
Non-IDU 1581 (7.6)
Not known 6579 (31.8)
Previous admission, alcohol-related Yes 6464 (31.2)
No 14256 (68.8)
Previous admission with cirrhosis Yes 734 (3.5)
No 19986 (96.5)
Previous admission with hepatitis B Yes 1166 (5.6)
No 19554 (94.4)
HCV¼hepatitis C virus; IDU¼current/former injecting drug user. An alcohol-related
admission is defined as hospitalisation with a discharge diagnosis code of at least one
of the following: (ICD-10) Z72.1, F10, G31.2, G62.1, G72.1, I42.6, K29.2, T51.0,
T51.9, K70.1-3, K86.0, Y90-1, R78.0, Z50.2, Z86.4, X45, X65, (ICD-9) 291, 303, 305,
357.5, 425.5, 535.3, 571.0-571.2, 790.3, E860.0, E860.9. Admission with cirrhosis is
defined similarly as follows: (ICD-10) K70.3, K74.6, (ICD-9) 571.2, 571.5, and
admission with hepatitis B is defined similarly as follows: (ICD-10) B16, B18.0, B18.1,
(ICD-9) 070.2, 070.3.
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d e a t hf r o ma n yc a u s ew e r e6 2a n d7 0 % .O ft h o s ew h od i e do fH C C ,
39% (42 out of 108) had a previous admission for cirrhosis, and 32%
(35 out of 108) had a previous alcohol-related admission.
DISCUSSION
In this study, we generated up-to-date estimates of the annual
incidence of HCC in the Scottish HCV-diagnosed population and
assessed the relative risk of developing HCC associated with
various variables. A key strength of this study is the use of national
data sources, which provided over 120000 person-years of follow-up.
The incidence of HCC increased over the period 1996–2006.
Consistent with this trend, there was an increasing trend in the
number of HCV-related deaths from liver cancer in Scotland over
the period 1996–2005 (Palmateer et al, 2007). Similar rising trends
in the incidence of HCV-related HCC have been observed over
overlapping periods in England (1996–2004; Sweeting et al, 2007)
and Australia (1990–2002; Amin et al, 2007).
Of those persons who died subsequent to their first hospitalisa-
tion with HCC, only 83% (95 out of 115) had HCC mentioned in
Table 2 Number of first-time hospital admissions/deaths with mention of HCV-related HCC over the period 1996–2006, by age at admission, sex, risk
group, and previous admission for cirrhosis
Year of admission/death Mean annual change
Level 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 % (95% CI) P
Age at admission/death
o5 0 55 1 21152334  0.9 ( 12.2, 10.5) 0.87
5 0 – 5 9 24 3 2193278 1 1 16.3 (6.1, 27.5) 0.001
6 0 + 59 1 68688695 2 . 7 (  4.6, 10.6) 0.48
All 12 18 5 10 10 16 16 12 16 20 20 6.1 (0.9, 11.6) 0.021
Sex
Male 11 14 4 8 9 14 14 7 14 17 18 6.4 (0.7, 12.4) 0.027
F e m a l e 45 1 21225232 4 . 5 (  7.7, 18.4) 0.49
Risk group
I D U 24 0 20211615 8 . 8 (  4.4, 23.8) 0.20
Non-IDU 2 3 1 2 2 1 33351 4 . 7 (  7.3, 18.4) 0.45
Not known 8 11 4 6 8 13 12 8 7 14 14 5.8 ( 4.5, 12.5) 0.70
Cirrhosis
N o 4 1 0 2 789789 1 29 6 . 7 (  0.3, 14.3) 0.060
Y e s 88 3 3279478 1 1 5 . 3 (  2.3, 13.5) 0.18
Alcohol
No 6 15 4 7 8 11 10 9 8 16 12 5.1 ( 1.1, 11.6) 0.11
Y e s 63 1 32563848 8 . 4 (  1.0, 18.6) 0.080
IDU¼injecting drug user. Presence of cirrhosis is ‘yes’ if patient had a previous hospital admission with mention of cirrhosis. Alcohol is ‘yes’ if patient had a previous hospital
admission with mention of alcohol.
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Figure 1 Proportion of individuals who were hospitalised or died with first-time mention of HCC over the period 1 January 1991 to 31 December 2006
as a function of (A) previous alcohol-related admission; (B) previous admission for cirrhosis; (C) sex; and (D) risk group.
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registry data may underestimate HCC incidence. This is particu-
larly relevant for modelling studies using back-calculation
methods to estimate the past incidence of chronic HCV infection
(Deuffic-Burban et al, 2004, 2007; Sweeting et al, 2007). Our
finding that only 40% of hospitalisations and 38% of deaths with
first-time mention of HCC had an HCV code listed also highlights
the limitations of registry methods.
In the general Scottish population, the overall incidence rate for
HCC in the period 1996–2004 was 2.9 per 100000 persons (ISD,
2008). Incidence was many times greater in the HCV-diagnosed
population; over the period 1996–2004, we obtained an SIR of 127,
five times larger than the SIR of 27 (95% CI: 23–31) in a New
South Wales (NSW), Australia, study (Amin et al, 2006; revised SIR
from J Amin, personal communication). This large discrepancy in
SIRs is attributable to differences in the definition of time at risk;
in the NSW study, the observation period is defined to start 1 year
after HCV diagnosis, as opposed to 14 days in this study. Notably,
the estimated prevalence of diagnosed HCV among all HCC cases
(8.8%) in Scotland was lower than the value (13.7%) reported for
NSW (Amin et al, 2007).
A shift in the incidence of HCC in one age group (40–60 years)
in a US population-based study has been reported (El-Serag and
Mason, 1999), reflecting the delay between disease onset and HCV
infection (thought to occur in the 1960s and 1970s). We observed
the largest average annual change in HCC incidence (16.3%) in the
50–59 years group; for these persons, the mean age at diagnosis
was 52, suggesting that infection occurred 20–25 years earlier, in
the 1970s.
Time-to-event analysis indicated that male sex, older age (50þ
years), and the occurrence of a previous hospital discharge for an
alcohol-related condition were all factors that greatly increased the
relative risk of developing HCC. These results concur with
previous research (Niederau et al, 1998; Schafer and Sorrell,
1999; Kuper et al, 2001).
Cirrhosis is an important risk factor for HCC, with HCC
developing in cirrhotic livers (irrespective of viral hepatitis
infection) with an annual incidence of 3% (Colombo et al, 1991;
Velazquez et al, 2003). An estimated 5–15% of chronic HCV-
infected individuals develop cirrhosis within 20 years after
diagnosis (Freeman et al, 2001; Seeff, 2002; Benvegnu ` et al,
2004). In HCV-infected patients with established cirrhosis, the
annual incidence and 5-year probability of HCC developing have
been estimated at 3.5% (Hutchinson et al, 2005) and 28–30%
(Benvegnu et al, 2004; Sola et al, 2006), respectively.
A previous admission with mention of cirrhosis was recorded
for 45% of HCC cases and was followed by hospital admission/
death with first-time mention of HCC at a median lag of 2.3 years.
Given the relatively young age distribution of the Scottish HCV-
diagnosed population (median age at diagnosis is 32) and the
relatively short observation time, the number of persons develop-
ing cirrhosis will be expected to increase as this population ages.
We expect to see a corresponding increase in the number of
individuals diagnosed with HCV infection who progress to HCC.
Previous hospital admission for an alcohol-related condition
was associated with a 2.6-fold increased risk of developing HCC.
Problem alcohol use, to the extent that it is captured by our proxy
variable, appear to be highly prevalent in our study population;
31% of the cohort had been previously admitted to hospital with
an alcohol-related diagnosis.
High levels of alcohol consumption, particularly above 350g per
week, have been associated with accelerated progression to
cirrhosis in chronic HCV-infected persons (Ostapowicz et al,
1998; Freeman et al, 2003; Monto et al, 2004). There is less
evidence that alcohol increases the risk of developing HCC once
cirrhosis is established (Adami et al, 1992; Teli et al, 1995;
Velazquez et al, 2003; Planas et al, 2004; also see Miyakawa et al,
1996; Tsutsumi et al, 1996), suggesting an indirect mechanism by
which alcohol increases the risk of HCC (Kuper et al, 2001). Given
the strong association between excessive alcohol intake and
cirrhosis, one measure for reducing the risk of HCC in the HCV-
infected population is to limit alcohol intake.
Development of HCC in HCV-infected persons usually requires
15–25 years (Schafer and Sorrell, 1999; Freeman et al, 2001); the
median lag between HCV diagnosis and hospitalisation/death with
first mention of HCC in our study was much shorter, 2.3 years. Our
study population, in particular those aged 40 and over at diagnosis,
were likely tested and diagnosed as HCV antibody positive many
years after infection, and in numerous cases, diagnosis was
concurrent to or shortly followed first hospital admission with
HCC. Given accurate data on the date of infection, we would expect
the time to HCC development to be more consistent with previous
studies.
The incidence of HCV-related HCC may have been under-
estimated due to (i) insufficient identifiers in the HCV Diagnosis
database for record linkage and (ii) an unknown, but likely small,
number of HCC cases that were not tested (and so never
diagnosed) for HCV infection during 1996–2006.
In conclusion, the significance of excess risk of HCC and the
trend for increasing annual numbers of 50- to 59-year-olds
developing HCC are consistent with ageing of the members of
the Scottish HCV-diagnosed population and the consequent
progression to severe liver disease. Our study has highlighted the
growing burden on public healthcare resources from HCV-related
outcomes such as HCC.
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